Healios K.K. (OTCMKTS:HLOSF – Get Free Report) saw a large drop in short interest in the month of April. As of April 30th, there was short interest totaling 263,933 shares, a drop of 34.6% from the April 15th total of 403,733 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days.
Healios K.K. Stock Performance
OTCMKTS:HLOSF remained flat at $2.20 during mid-day trading on Monday. Healios K.K. has a 12-month low of $1.90 and a 12-month high of $4.45. The firm has a 50 day moving average of $2.40 and a two-hundred day moving average of $2.46.
About Healios K.K.
Healios K.K. is a Tokyo–based biotechnology company focused on the development and commercialization of regenerative medicine products and services. The company’s core expertise lies in induced pluripotent stem cell (iPSC)–derived therapies, with a pipeline that includes retinal pigment epithelium (RPE) cells for age‐related macular degeneration and neural cell products targeting neurological disorders. Healios operates a specialized cell processing center in Chuo‐ku, Tokyo, adhering to stringent quality standards for clinical‐grade cell manufacturing.
Beyond its proprietary programs, Healios provides contract development and manufacturing services (CDMO) to pharmaceutical and research institutions.
Further Reading
- Five stocks we like better than Healios K.K.
- Iran Ceasefire Trade: 3 Energy Stocks to Own if Oil Falls to $80
- Willing and Abel: Berkshire’s New CEO Makes Huge Portfolio Changes in Q1
- Insider Buying Says Upstart Isn’t Down for the Count
- These Stocks Could Be the Biggest Winners of the 2026 Midterms
Receive News & Ratings for Healios K.K. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healios K.K. and related companies with MarketBeat.com's FREE daily email newsletter.
